Last reviewed · How we verify
Buccal Buprenorphine 300 mcg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Buccal Buprenorphine 300 mcg (Buccal Buprenorphine 300 mcg) — Vanderbilt University Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Buccal Buprenorphine 300 mcg TARGET | Buccal Buprenorphine 300 mcg | Vanderbilt University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Buccal Buprenorphine 300 mcg CI watch — RSS
- Buccal Buprenorphine 300 mcg CI watch — Atom
- Buccal Buprenorphine 300 mcg CI watch — JSON
- Buccal Buprenorphine 300 mcg alone — RSS
Cite this brief
Drug Landscape (2026). Buccal Buprenorphine 300 mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/buccal-buprenorphine-300-mcg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab